Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41882358.
- Also identified by DOI 10.1038/s41586-026-10264-6 and PMC identifier 13083265.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Posterior fossa type A (PFA) ependymoma is an unusual infantile brain tumour with few known somatic mutations, thought to be driven by epigenetic mechanisms<sup>1</sup>. PFA ependymoma has a markedly higher incidence and worse prognosis in male children than in female children<sup>2</sup>. The mechanisms that underlie these sex differences are at present unknown. Here we show that the cellular hierarchy of PFA ependymoma is less differentiated in male individuals than it is in female individuals. In the normal developing mouse hindbrain, male gliogenic progenitors are less differentiated than matched female sibling controls. To further parse the effects of chromosomal versus gonadal contributions in the male hindbrain, we used the four-core genotype mouse model<sup>3</sup>, which showed that androgen signalling, rather than sex chromosomes, prolongs hindbrain differentiation in male mice. Androgen supplementation promotes the growth of PFA ependymoma, but not that of other brain tumours. Conversely, androgen blockade diminishes both the stem-like potential and the proliferation of PFA ependymoma. We conclude that androgen signalling in both the normal developing hindbrain and PFA ependymoma is sufficient to promote growth and delay differentiation. Anti-androgen therapies represent a potential clinical avenue to target this currently untreatable childhood cancer.
Medical subject headings
- Rhombencephalon
- Androgens
- Ependymoma
- Brain Neoplasms